

# Alexis Rompré©-Brodeur

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1521981/publications.pdf>

Version: 2024-02-01

19  
papers

179  
citations

1307366

7  
h-index

1372474

10  
g-index

22  
all docs

22  
docs citations

22  
times ranked

360  
citing authors

#	ARTICLE	IF	CITATIONS
1	Minority Enrollment in Phase II and III Clinical Trials in Urologic Oncology. <i>Journal of Clinical Oncology</i> , 2022, 40, 1583-1589.	0.8	14
2	MRI-guided fusion biopsy of the prostate resection bed among post-radical prostatectomy patients with rising PSA. <i>Journal of Clinical Oncology</i> , 2021, 39, 208-208.	0.8	0
3	The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy. <i>Journal of Urology</i> , 2021, 206, 1157-1165.	0.2	10
4	Role of Systematic Control Biopsies following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 1177-1183.	0.2	4
5	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 1183.	0.2	0
6	Kidney cancer: from genes to therapy. <i>Current Problems in Cancer</i> , 2021, 45, 100773.	1.0	5
7	MP42-18â€fMANAGEMENT OF HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER (HLRCC)-ASSOCIATED RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
8	MP45-09â€fACTIVE SURVEILLANCE IN NONHEREDITARY BILATERAL MULTIFOCAL TYPE I PAPILLARY RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
9	PD40-11â€fCLINICAL ACTIVITY OF NIVOLUMAB IN ADVANCED HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER (HLRCC)-ASSOCIATED KIDNEY CANCER. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
10	MP61-15â€fPREDICTING RENAL FUNCTIONAL OUTCOMES AFTER PARTIAL NEPHRECTOMY: A COMPARISON OF NEPHROMETRY SYSTEMS. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
11	PD46-03â€fEXAMINING MINORITY ENROLLMENT IN CLINICAL TRIALS IN UROLOGIC ONCOLOGY. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
12	PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: <i>In Situ</i> and Abscopal Effects. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 211-220.	1.9	32
13	PD17-12â€fONCOLOGICAL OUTCOMES OF FOCAL HIGH-INTENSITY FOCUSED ULTRASOUND FOR INTERMEDIATE RISK PROSTATE CANCER TREATMENT: A FIRST NORTH AMERICAN EXPERIENCE WITH FOCAL ONE Â®. <i>Journal of Urology</i> , 2020, 203, .	0.2	0
14	Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronieâ€™s Disease. <i>Sexual Medicine</i> , 2019, 7, 459-463.	0.9	17
15	MP57-11â€fPD-1/PD-L1 IMMUNE-CHECKPOINT INHIBITION WITH RADIATION IN BLADDER CANCER: IN SITU AND ABS COPAL EFFECTS. <i>Journal of Urology</i> , 2019, 201, .	0.2	0
16	18F-fluorocholine positron emission tomography-computed tomography (18F-FCH PET/CT) for staging of high-risk prostate cancer patients. <i>Canadian Urological Association Journal</i> , 2018, 13, 84-91.	0.3	4
17	Adult Bilateral Ureterocele Presenting with Lower Urinary Tract Symptoms and Acute Urinary Retention. <i>Case Reports in Urology</i> , 2018, 2018, 1-5.	0.1	7
18	Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1618-1629.	2.1	75

#	ARTICLE	IF	CITATIONS
19	Affinity Purification of RNA Using an ARiBo Tag. <i>Methods in Molecular Biology</i> , 2013, 941, 137-155.	0.4	11